Clinical Trials

32 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

270 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

70 enrolled

Urothelial Bladder Carcinoma

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

10 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06727565 2026-03-02

VELOCITY-HNSCC

100 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

200 enrolled

Tumor-Agnostic

Neoplasms

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Phase 1/2 Suspended

46 enrolled

Phase 2 Not yet recruiting

Pancreatic Neoplasms

NCT07424664 2026-02-20

A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer

30 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

1,021 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

182 enrolled

Other solid neoplasm

Solid Tumor

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

33 enrolled

Phase 2 Not yet recruiting

Bile Duct Neoplasms, Cholangiocarcinoma

NCT07337447 2026-01-13

REWENEC 01

122 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT05007782 2025-12-29

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase 1 Recruiting

416 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2 Withdrawn

Stomach Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase 1/2 Recruiting

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

227 enrolled

Colorectal Neoplasms

NCT05886634 2025-10-20

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

16 enrolled

Sarcoma

Liposarcoma, Sarcoma

NCT06790706 2025-10-06

IMMUNORARE5

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

154 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT05676931 2025-10-02

EDGE-Lung

400 enrolled

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Advanced Non-Small Cell Lung Cancer

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

94 enrolled

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05024097 2025-08-27

PANTHER

43 enrolled

Rectal Neoplasms

NCT04262856 2025-08-26

ARC-7

Phase 2 Completed

151 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

173 enrolled